Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
A gene known to promote longevity in animals has now been discovered to encode a tumor suppressor – a protein that helps prevent cancer, according to a study by a team of scientists from The University of Texas M. D. Anderson Cancer Center. The new gene, which was inactivated in two-thirds of patients studied, presents a potent new target for breast cancer therapy, the researchers say.
St. John’s wort, an herb thought to be a safe, natural remedy for mild depression, may interfere with a powerful cancer-fighting drug’s ability to prevent relapse in leukemia patients, a University of Florida pharmacy researcher will report March 27 at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.
Scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute have found mutations in a gene linked to the progression of colon and other cancers. The research findings, may lead to new therapies and diagnostic tests that target this gene.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.